Moderna Inc [MRNA] stock prices are down -0.76% to $43.06 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MRNA shares have gain 12.58% over the last week, with a monthly amount drifted -21.31%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on November 19, 2024, when Berenberg initiated its Hold rating and assigned the stock a price target of $42. Previously, HSBC Securities upgraded its rating to Buy on November 18, 2024, and kept the price target unchanged to $58. On November 15, 2024, Wolfe Research initiated with a Underperform rating and assigned a price target of $40 on the stock. Bernstein started tracking the stock assigning a Mkt Perform rating and suggested a price target of $55 on October 17, 2024. Oppenheimer downgraded its rating to a Perform. JP Morgan downgraded its rating to Underweight for this stock on September 13, 2024, and downed its price target to $70. In a note dated September 13, 2024, Jefferies downgraded an Hold rating on this stock and revised its target price from $120 to $65.
The stock price of Moderna Inc [MRNA] has been fluctuating between $35.80 and $170.47 over the past year. Currently, Wall Street analysts expect the stock to reach $140.57 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $43.06 at the most recent close of the market. An investor can expect a potential return of 226.45% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
The Moderna Inc [NASDAQ:MRNA] reported sales of 5.07B for trailing twelve months, representing a surge of 1.69%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.53%, Pretax Profit Margin comes in at -0.46%, and Net Profit Margin reading is -0.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.18 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.29 points at the first support level, and at 41.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.84, and for the 2nd resistance point, it is at 44.62.
Ratios To Look Out For
It’s worth pointing out that Moderna Inc [NASDAQ:MRNA]’s Current Ratio is 4.39. In addition, the Quick Ratio stands at 4.20 and the Cash Ratio stands at 0.75. Considering the valuation of this stock, the price to sales ratio is 3.24, the price to book ratio is 1.39.
Transactions by insiders
Recent insider trading involved Hoge Stephen, Officer, that happened on Nov 29 ’24 when 291.0 shares were purchased. Officer, Klinger Shannon Thyme completed a deal on Nov 29 ’24 to buy 1418.0 shares. Meanwhile, Officer Mock James M bought 1420.0 shares on Nov 29 ’24.
